Introduction
============

Neuroacanthocytosis (NA) syndromes encompass a group of rare diseases characterized by the presence of "thorny" red blood cells (acanthocytes) in peripheral blood smear and neurodegeneration of the basal ganglia, along with hyperkinetic movement, seizures, cognitive impairment, and neuropsychiatric manifestations ([@B31]). Chorea-acanthocytosis (ChAc, OMIM 200150) occupies the main entity of this disease group which also includes McLeod syndrome (MLS), Huntington's disease-like 2 (HDL2) and, more rarely, pantothenate kinase-associated neurodegeneration (PKAN) ([@B31]). From a perspective of genotype, ChAc mainly follows an autosomal recessive (AR) inheritance pattern ([@B7]), and the causative gene is vacuolar protein sorting 13A (*VPS13A*), a large gene consisting of 73 exons located in chromosome 9q21 ([@B34]). Up to now, the *VPS13A* gene mutation types reported ever include missense, nonsense, frameshift, duplication, deletion and splice site mutations ([@B29]). Chorein, the *VPS13A* gene expression product, is ubiquitously detected in a wide variety of human tissues ([@B10]), which has been proven to be markedly reduced or absent in ChAc patients with the mutations described above ([@B10]; [@B29]). While viewing from phenotypic aspects, ChAc can manifest as chorea, dystonia, cognitive impairment, seizures, psychosis, and even Parkinsonian features ([@B27]), thus bearing immense resemblance to Huntington's disease, dystonia, epilepsy, Parkinsonism, etc. Hence, the multifarious *VPS13A* mutation patterns, intricate symptom complex and overlapped clinical features enable diagnosis and differential diagnosis of ChAc an enormous challenge.

Herein, we report two clinical cases diagnosed with ChAc, varying from *VPS13A* mutation patterns, presenting manifestations, symptom spectrum to laboratory biomedical indicators. After a retrospective review of the ChAc case ever reported, we regrettably find that few cases are from China. Moreover, in light of the sharp contrast between population base and reported cases in China and the global prevalence of ChAc, it can be concluded that the morbidity of ChAc has been underdiagnosed in China ([@B21]). Based on the ChAc literatures ever published and these two cases, we conclude several suggestive features and propose a diagnostic path of ChAc, aiming to facilitate the future diagnosis and management of ChAc in China.

Case Presentation
=================

Two confirmed ChAc patients, once admitted into Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (TJMC, HUST), were interviewed and surveyed retrospectively, and their medical records were thoroughly reviewed. Besides, relevant clinical and imaging data during the periodic outpatient follow-ups were consulted as well.

Ethics Statement
----------------

This study was carried out in accordance with the guidelines of institutional ethics committee of Union Hospital, TJMC, HUST. All subjects gave written informed consent on the basis of the Declaration of Helsinki.

Case 1
------

A 37-year-old man, a warehouse keeper, presented with perioral chorea, dysphagia, dysarthria, vocalization, and involuntary upper limb movements for 5 months. His symptoms had been gradually progressing, aggravated recently by involuntary self-mutilation behaviors: tongue and lip biting. The past history revealed that he was diagnosed with generalized tonic--clonic seizure (GTCS) at age 30, but maintaining continuous remission with regular sodium valproate administration. On neurological examination, the patient showed perioral chorea, reduced muscle tone and tendon reflex and sporadic mouth ulcers, especially accompany frequent suck-mimicking activity. Upon admission screening stage, the laboratory biomedical tests revealed a considerable elevation in serum creatine kinase (CK), l-lactate dehydrogenase (LDH) and alpha hydroxybutyrate dehydrogenase (HBDH), especially for CK reaching up to seven-fold (see **Table [1](#T1){ref-type="table"}**). The subsequent brain magnetic resonance imaging (MRI) scanning indicated moderate anterior horn dilation of lateral ventricles and mild caudate nucleus head atrophy (see **Figure [1A](#F1){ref-type="fig"}**-left column). Based on the clinical features, neurological examination findings and auxiliary test results available, we proposed the probable diagnosis of ChAc. Then four repeated and independent blood smears were performed, revealing that acanthocytes ratio averaged to 18% of the complete blood count (CBC) (see **Figure [1B](#F1){ref-type="fig"}**-left column). To further confirm the diagnosis, the *VPS13A* gene was sequenced subsequently. As expected, a heterozygous frameshift mutation in exon 52 (c.7276_7280delCAATA) and a heterozygous nonsense mutation in exon 60 (c.8278C\>T) had been determined, which probably gave rise to the premature translation termination and even nonsense-mediated decay (NMD) pathway induced *VPS13A*-mRNA degradation ([@B19]) (see **Figure [2A](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Besides, subsequent Sanger sequencing also confirmed the heterozygous frameshift and nonsense mutations (see **Figure [2A](#F2){ref-type="fig"}**). Moreover, the *HD-IT15* gene (CAG)~n~ analysis had also been performed to exclude the possible comrbidity of HD, but revealing no pathogenic mutations. In conclusion, the patient was ultimately diagnosed with ChAc and prescribed haloperidol, tiapride to control his perioral chorea ([@B8]). Besides, given that vitamin E was once reported to relieve ChAc symptoms by means of improving red blood cell membrane fluidity ([@B13]), it was tentatively administrated as well. As a result, his perioral chorea and self-mutilation behaviors were alleviated 3 days later and he was discharged after a week of clinical observation.

###### 

A summary of the diagnostic evidences identified in the affected ChAc patients.

  Items                              Patient 1                                                                   Patient 2
  ---------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------
  Gender/age at onset                Male/37                                                                     Female/45
  Occupation                         Warehouse keeper                                                            Housewife
  Family history                     --                                                                          --
  Primary symptoms                   Perioral chorea, frequent sucking--mimicking                                Bruxism, involuntary tongue and lip biting
  Incipient symptom                  GTCS                                                                        Bruxism
  Dystonia distribution              Oromandibular region, upper limbs                                           Oromandibular region
  Dysarthria                         +++                                                                         \+
  Tongue and lip biting              \+                                                                          +++
  Parkinsonian features              --                                                                          --
  Tendon reflex                      Areflexia of four limbs                                                     Hyporeflexia of lower extremities
  Seizure type                       GTCS                                                                        --
  Cognitive impairment               ++                                                                          \+
  Psychiatric symptoms               Apathy, depression                                                          Apathy, anxiety
  EMG                                Axonal neuropathy                                                           Axonal neuropathy
  CK (38-170U/L)                     1122                                                                        137
  LDH (109-245U/L)                   314                                                                         175
  HBDH (72-182U/L)                   247                                                                         159
  ALT (5-40U/L)                      34                                                                          14
  AST (8-40U/L)                      47                                                                          15
  Acanthocyte ratio of CBC           18%                                                                         17%
  MRI                                Moderate caudate nucleus head atrophy and paracele anterior horn dilation   Mild caudate nucleus head and putamen atrophy
  *HD-IT15* gene (CAG)~n~ analysis   No pathogenic mutation                                                      No pathogenic mutation
  *VPS13A* sequence changes          c.7276_7280delCAATA c.8278C\>T                                              c.8282C\>G c.9276-1G\>A
  Chorein alterations                p.Gln2426GlnfsX7 p.Gln2760Ter                                               p.Ser2761Ter Splicing mutation
  Mutation types                     Frameshift mutation (exon52) Nonsense mutation (exon60)                     Nonsense mutation (exon60) Splicing mutation (intron69)
                                                                                                                 

(+++, severe; ++, moderate; +, mild; --, none); GTCS, generalized tonic--clonic seizure; CK, creatine kinase; LDH, l-lactate dehydrogenase; HBDH, alpha hydroxybutyrate dehydrogenase; ALT, alanine transaminase/glutamic-pyruvic transaminase; AST, aspartate transaminase/glutamic--oxaloacetic transaminase; HD, Huntington's disease; EMG, electromyography; CBC, complete blood count; Gln, glutamine; Ser, serine; Ter, termination codon.

![**Neuroimaging and cytological features identified in ChAc patients.** **(A)** Axial and coronal view of the basal ganglion plane in patient 1 (left) and patient 2 (right) demonstrated similar MR imaging features: caudate nucleus head atrophy and anterior horn dilation of lateral ventricles (marked by arrows). **(B)** Acanthocytes (marked by arrows, Giemsa staining) were detected in peripheral blood smear under light microscope examination. The average acanthocytes ratio in patient 1 and 2 were 18% (left) and 17% (right), respectively. **(C)** Schematic diagram of striatal atrophy pattern in ChAc patient. The caudate nucleus head atrophy demonstrated a dorsal to ventral pattern (marked by yellow), while the putamen presented a caudate to rostral mode (marked by black).](fnagi-09-00095-g001){#F1}

![**Sequencing analysis of the *VPS13A* gene in ChAc patients and family member.** **(A)** High-throughput sequencing of *VPS13A* gene (NM_033305) in patient 1 reveals a 5 bp heterozygous deletion (c.7276_7280delCAATA) in exon 52 (A1) and a substitution of T for C (c.8278C\>T) in exon 60 (A2). Moreover, the frameshift mutation and nonsense mutation have been confirmed by the Sanger sequencing method precisely. **(B)** Chip capture high throughput sequencing of *VPS13A* gene (NM_033305) in patient 2 shows a substitution of G for C (c.8282C\>G) in exon 60 (B1) and an aberrant splicing pattern (c.9276-1G\>A) in intron 69 (B2). While, in contrast, her daughter only shows a heterozygous splicing mutation similar to her mother's in intron 69 (c.9276-1G\>A) (B2), but not the nonsense one in exon 60 (B1).](fnagi-09-00095-g002){#F2}

Case 2
------

A 45-year-old housewife gradually developed involuntary bruxism (teeth grinding), dysphagia, dysarthria, vocalization, and frequent self-mutilation behaviors (tongue and lip biting) after a recovery from a severe mouth ulcer 1 month ago. Her orofacial chorea was characterized by clumsy, non-coordinated mandibular movement and occasional grimacing activities. A further family history inquiry revealed no similar symptom presenters. On neurological examination, she showed frequent teeth clenching, reduced limb muscle tone and tendon reflex and multiple lip ulcers. To prevent the risk of self-mutilation, she had to continuously hold a roll of cloth in her mouth. The serum CK, LDH, and HBDH levels are all within normal ranges (see **Table [1](#T1){ref-type="table"}**). On the basis of clinical features and serum biomchemical indicators, the patient was temporarily diagnosed with oromandibular dystonia. But a routine blood smear test accidentally detected acanthocytes, which thereby led us to the assumptive diagnosis of ChAc. Subsequently, three repeated and independent peripheral blood smears conformably detected acanthocytes, with acanthocytes ratio averaged to 17% of CBC (see **Figure [1B](#F1){ref-type="fig"}**-right column). Besides, brain MRI scanning demonstrated mild atrophy in the caudate head and putamen bilaterally, accompanying moderate anterior horn dilation of lateral ventricles (see **Figure [1A](#F1){ref-type="fig"}**-right column). Moreover, the *VPS13A* gene sequencing further confirmed the diagnosis, revealing a heterozygous nonsense mutation (c.8282C\>G→p.Ser2761Ter) in exon 60 and a heterozygous splicing mutation (c.9276-1G\>A) in intron 69 (see **Figure [2B](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Nevertheless, the *VPS13A* gene sequencing in this patient's daughter, a healthy girl with no sign of ChAc, identified a heterozygous splicing mutation similar her mother's in intron 69 (c.9276-1G\>A) (see **Figure [2B](#F2){ref-type="fig"}**). As a matter of fact, the inheritance pattern of ChAc was reported to vary from AR inheritance (predominant pattern), autosomal dominant inheritance to X linked recessive inheritance pattern ([@B27]; [@B9]), accompanying different levels of penetrance in different sufferers or families ([@B25]; [@B32]). Therefore, when postulating that ChAc is inherited in an AR inheritance and complete penetrance pattern in this family, the healthy girl is probably a carrier of pathogenic *VPS13A* gene. In conclusion, according to the clinical symptoms, neuroimaging features and, especially, genetic findings, the patient was finally diagnosed with ChAc. Then the patient received botulinum toxin (BTX) injection to relieve her torturous bruxism and self-mutilation behavior, eventually achieving prominent remission. In the outpatient follow-up 4 months later, she was also routinely prescribed haloperidol and vitamin E to control chorea ([@B8]) and improve the red blood cell membrane fluidity ([@B13]) and it subsequently presented satisfactory therapeutic effects.

Discussion and Literature Review
================================

In this study, we present two ChAc cases on the basis of clinical symptoms, neuroimaging features, and *VPS13A* genetic findings. While a retrospective study of the ChAc cases ever reported revealed that there probably exists a considerable underdiagnosis of ChAc in China ([@B21]). Given this stern status quo of ChAc management, we propose several suggestive features and a diagnostic path of ChAc (see **Table [2](#T2){ref-type="table"}**), which can be used to facilitate the diagnosis and management of ChAc in China.

###### 

Proposed diagnostic path of ChAc.

  Evidence Categories                Details
  ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  I. Clinical clues (is mandatory)   ① Hyperkinetic movements (e.g., perioral or oromandibular dystonia, feeding dystonia; grimacing activities, limb choreic movements) *most common cues*
                                     ② Self-mutilation behaviors (especially tongue and lip biting; sporadic mouth ulcers) *most suggestive cues*
                                     ③ Bruxism (teeth grinding behaviors)
                                     ④ Dysarthria, dysphasia, articulation disorders
                                     ⑤ Seizures attack (GTCS, simple or complex partial seizures)
                                     ⑥ Parkinsonian symptoms (e.g., bradykinesia, rigidity)
                                     ⑦ Neuropsychiatric symptoms (e.g., apathy, anxiety, depression, agitation, cognitive impairment)
                                     ⑧ Diminished or absent tendon reflex (axonal neuropathy proved by EMG)
  II\. Neuroimaging traits           ⑨ Caudatum (especially caudate nucleus head) and lenticula atrophy (determined by striatal volumetry and morphometry), anterior horn dilation of lateral ventricles
  III\. Laboratory inspection        ⑩ Serum chemistry indicators: CK, LDH, HBDH, ALT, and AST elevation *CK elevation, comparatively more specific indicator*
                                     ⑪ Acanthocyte detection (peripheral blood smear or scanning electron microscope inspection) *most suggestive evidence*
                                     ⑫ Chorein detection (reduced or absent chorein blot) *most confirmatory evidence*
  IV\. *VPS13A* gene sequencing      ⑬ Pathogenic *VPS13A* mutation (e.g. missense, nonsense, frameshift, duplication, deletion, and splice site mutations) *most confirmatory evidence*
                                     

The diagnosis of ChAc is proposed to be established on the basis of four categorical evidences: clinical clues, neuroimaging traits, laboratory inspection, and

VPS13A

gene sequencing. According to different evidence combinations, the diagnosis of ChAc can be classified into three subcategories: possible ChAc, probable ChAc, and definite ChAc.

\(1\) Possible ChAc: ① ② + ⑨ or ⑩ are mandatory, optional items from ③ - ⑧ (excluding other organic diseases and dystonia);

\(2\) Probable ChAc: ① ⑪ are mandatory, optional items from ② - ⑬ (excluding other organic diseases and dystonia);

\(3\) Definite ChAc: ① + ⑫ or ⑬ are mandatory, optional items from ② - ⑪ (excluding other organic diseases and dystonia)

Attention: Apart from the mandatory items, the more supportive evidences, the more definite of the establishment of each diagnostic subcategory.

Clinical Features
-----------------

Chorea-acanthocytosis mostly present in early adulthood, between age 20 and 40 and rarely before age 20 or after 50 ([@B32]), generally with hyperkinetic involuntary movements as typical symptoms ([@B30]). As a matter of fact, perioral chorea, bruxism and self-mutilation behaviors, demonstrated by the two patients, are all concrete manifestations of the hyperkinetic movements (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**). In particular, several previous reports have already indicated that self-mutilation, especially tongue and lip biting, were critically suggestive of ChAc ([@B33], [@B32]; [@B12]) (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**). What is interesting is that the self-mutilation behaviors can be considerably alleviated by holding a roll of cloth in mouth just as performed by patient 2. This phenomena can be interpreted as direct mechanic protections or a certain form of sensory trick ([@B3]; [@B30]).

Seizures and neuropathy are also relatively common features of ChAc (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**). It has been speculated that about 42% of patients have at least one seizure attack during their clinical courses ([@B24]). In general, seizure are mostly antiepileptic drugs (AEDs) sensitive GTCS in ChAc, just as proven in patient 1, but simple and complex partial seizures have been described as well ([@B2]; [@B32]). For example, a recent study had identified a rare c.2343del *VPS13A* gene mutation in three Israeli families, in which most affected individuals presented seizures as the first and dominant symptom ([@B5]). Moreover, seizures of this type could be of temporal lobe origin and were AEDs resistant in five out of nine patients ([@B5]). Peripheral sensorimotor neuropathy with the absence of deep tendon reflexes is common in NA, and it can be no easy to differentiate from motor neuron disease ([@B23]). Nevertheless, the neuroelectrophysiological abnormities predominantly prove to be axonal neuropathy in ChAc ([@B32]) (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**), which is quite different from that of motor neuron disease.

Dysphagia and dysarthria are also common symptoms in ChAc (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**), resulting from progressive swallowing and vocal musculature dysfunction. While in the initial stages swallowing and speech impairment are likely due to orolingual dystonia, patients often become mute as the disease proceeds into terminal stages, thus implying an involvement of central nervous system dysfunction ([@B30]). Additionally, Parkinsonism are also involved in the symptom spectrum as a presenting or accompanying symptom, especially in later stage with the encroachment of the direct and indirect pathways ([@B6]).

Patients diagnosed with ChAc often present neuropsychiatric symptoms prior to the development of movement disorders ([@B30]). In general, psychiatric symptoms include apathy, anxiety, depression, obsessive-compulsive disorders, and agitation, which are also precisely confirmed by the affected patients in this study (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**). Cognitive impairments range from mild cognitive impairment to dementia, with deficits mainly manifesting as memory decline and executive dysfunction.

Serum biochemistry reveals that CK, LDH, and HBDH are elevated in the vast majority (about 85%) of ChAc patients and it may precede the appearance of neurologic symptom as a sign of subclinical myopathy ([@B22]; [@B30]). However, the serum biochemical alteration are not mandatory for the diagnosis of ChAc, just as proven by patient 2 whose CK, LDH, and HBDH values are all within normal ranges (see **Table [1](#T1){ref-type="table"}**). Nevertheless, CK elevation is not associated with HDL2, PKAN, and HD, thus enabling serum CK a relatively more specific indicator for ChAc (see **Table [2](#T2){ref-type="table"}**) especially in China when compared with other biochemical indicators ([@B21]).

Acanthocyte detection in peripheral blood smear is a specific indicator for the diagnosis of ChAc (see **Figure [1B](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). However, the detection efficiency of acanthocytes is largely dependent on several specific endogenous factors and blood sample treatment methods, and their absence does not absolutely exclude the diagnosis of ChAc ([@B4]). Scanning electron microscopy is the most reliable morphological diagnostic method, but it is still not routinely popularized. Therefore, chorein detection ([@B29]) or *VPS13A* gene sequencing ([@B34]) can be proposed to be alternatives in the scenario of acanthocyte detection failure.

Genetic Findings
----------------

ChAc, an AR inherited movement disorder, can be attributed to *VPS13A* gene mutation on chromosome 9q21. The previously reported *VPS13A* mutation patterns include missense, nonsense, frameshift, duplication, deletion, and splice site mutations ([@B10]). In this study, the *VPS13A* gene sequencing in patient 1 revealed a heterozygous frameshift mutation in exon 52 (c.7276_7280delCAATA) and a heterozygous nonsense mutation in exon 60 (c.8278C\>T), while in patient 2 and her daughter identified a heterozygous nonsense mutation (c.8282C\>G) in exon 60 and a heterozygous splicing mutation (c.9276-1G\>A) in intron 69 (see **Figure [2](#F2){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). In general, the mutations described above may probably give rise to premature translation termination, NMD pathway induced *VPS13A*-mRNA degradation ([@B19]), abnormal spliceosome formation and even production of aberrant chorein, which can genetically contribute to the occurrence of ChAc.

What is interesting is that a recent study revealed a rare c.2343del mutation in three ChAc Israeli families in which seizures present as the premier and prominent symptoms ([@B5]). Moreover, the seizures presented in these families were, in large part, of temporal origin and partly AEDs resistant ([@B5]). A retrospective review of ever published literatures indeed indicates the presence of epilepsy at early stages of NA ([@B14]; [@B26]; [@B18]; [@B1]; [@B2]), but scarcely in the case of ChAc. In comparison, orofacial and oromandibular chorea are typical symptom in both affected patients in our study, but the presenting symptom in patient 1 is GTCS while in patient 2 is bruxism (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**). Given the novel and disparate *VPS13A* gene mutations identified in patient 1 and patient 2, it can be presumed that particular incipient symptoms may be associated with some specific *VPS13A* mutations, just as corroborated by the relevance of c.2343del mutation to epilepsy in Israeli families ([@B5]). Nevertheless, restricted by the sample sizes in this study, it is imperative to investigate the intriguing proposition of genotype--phenotype correlation in larger ChAc groups in future study.

Hence, in light of the miscellaneous incipient symptom at early stages of ChAc, the *VPS13A* gene sequencing can be regarded as a reliable diagnostic and research tool. As a matter of fact, it is precisely the novel *VPS13A* gene mutations have finally helped to confirm the suspected ChAc cases in this study.

Neuroimaging Traits
-------------------

The ChAc patients, on postmortem, typically presented atrophy of the caudate nucleus, putamen, and globus pallidum, in some cases involving substantia nigra as well, but usually sparing cerebral cortex, cerebellum, locus coeruleus, inferior olives, and other brain regions ([@B14]; [@B15]). From a neuropathological perspective, marked neuronal loss and astrocytic gliosis were frequently observed, especially in the caudate nucleus ([@B17]). Brain MR scanning in established ChAc patients also mirrored these findings, demonstrating similar macroscopic features, with caudate nucleus head being the most vulnerable region ([@B36]; [@B17]) (see **Figures [1A,C](#F1){ref-type="fig"}**).

Given the significance of caudate nucleus in ChAc, several neuroimaging studies on caudate nucleus volume and shape alterations had been performed. By means of voxel-based morphometry (VBM) approach, [@B15] reported a focal and symmetrical atrophy in the caudate nucleus when comparing six patients with 15 age-matched controls. Later, [@B16] further confirmed the conclusion with normalized VBM which could distinguish ChAc solely on the basis of caudate volumetry. These two studies had proven volume reduction in caudate nucleus and established a neuroimaging indicator (caudate volumetry) in the diagnosis of ChAc, but not investigating the morphometric changes. [@B35] advanced the study with the help of non-parametric spherical harmonic technique which confirmed marked caudate shape alterations in ChAc. Nevertheless, the shape and volume alterations did not manifest uniformly, but with a prominent predilection to caudate nucleus head ([@B35]) (see **Figures [1A,C](#F1){ref-type="fig"}**). More specifically, the caudate nucleus atrophy revealed a dorsal to ventral gradient, while in putamen demonstrated a caudal to rostral pattern ([@B35]) (see **Figure [1C](#F1){ref-type="fig"}**). This particular pathological changes might be associated with the neuropsychiatric or cognitive symptoms in the early stage of ChAc, in light of the crucial role of caudate nucleus in frontostriatal loops ([@B20]; [@B11]; [@B28]). In conclusion, based on the neuroimaging features identified in ChAc, the striatal volumetry and morphometry could be proposed as promising neuroimaging diagnostic indicators in future clinical practice.

Conclusion
==========

Here in this study, we present the clinical symptoms, neuroimaging features and *VPS13A* gene sequencing results of two patients, which all finally support the diagnosis of ChAc. Besides, four novel *VPS13A* gene mutations have been identified, which genetically corroborate the pathogenesis of ChAc and expand the *VPS13A* gene mutation spectrum as well. Nevertheless, it has been revealed that only a handful of cases are from China in a retrospective review of the published ChAc cases ([@B21]). Hence, in light of China's tremendous population base, rare ChAc case reports and the overall prevalence worldwide, it can be presumed that there may exist an underdiagnosis of ChAc in China ([@B21]).

Confronted with such frustrating status quo, we have concluded several suggestive indicators and proposed a diagnostic path of ChAc on the basis of ever published reports and the present two cases, which falls into the range of clinical clues, neuroimaging traits, laboratory inspections and genetic findings, respectively: (1) clinical clues: oromandibular and feeding dystonia, self-mutilation behaviors (tongue and lip biting); (2) neuroimaging traits: paracele anterior horn dilation and caudate nucleus head atrophy; (3) laboratory inspections: serum CK elevation and acanthocytes detection; (4) genetic findings: familial aggregation, positive family history, and pathogenic *VPS13A* gene mutations discovery; (see **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**). In conclusion, we expect the reported cases and proposed diagnostic path could facilitate the future diagnosis and management of ChAc in China.
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